OnCusp Therapeutics is a biopharma company focused on translating preclinical oncology innovation into clinically validated treatments. Its lead asset, CUSP06, is a CDH6‑targeting antibody‑drug conjugate with preclinical data showing increased potency, bystander effect, linker stability, and potential to overcome drug resistance. CUSP06 obtained FDA IND clearance in 3Q 2023 and is planned for a first‑in‑human Phase I study in the U.S. The company secured an oversubscribed $100 million Series A to advance CUSP06 toward clinical proof‑of‑concept and to expand its portfolio and team. OnCusp has global rights (outside China) to CUSP06 from Multitude Therapeutics and lists WuXi XDC as the CMC partner for the program. Since its establishment in April 2021, OnCusp has raised $139 million in total. OnCusp focuses on advancing preclinical oncology candidates—including bispecific antibodies, antibody-drug conjugates (ADCs), and small molecules—toward clinical proof-of-concept. The company in-licenses preclinical drug candidates from the U.S., China and other regions and advances them into global early clinical development. OnCusp aims to out-license assets to multinational pharmaceutical companies after establishing clinical POC. The founding team has deep experience in business development and oncology translational and clinical development. The company opened operations in New York and Shanghai and is building a portfolio of high-potential oncology assets. OnCusp completed a $25 million seed financing to support pipeline development, R&D programs, day-to-day operations, and talent acquisition.

Total raised

$125M

Funding rounds

2

Latest round

Series A

Latest activity

Jan 2024